WEST LAFAYETTE, Ind., Dec. 16, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced preclinical data suggesting the company’s folate receptor-targeted SMDCs may provide a possible new treatment alternative for folate receptor expressing triple negative breast cancer (TNBC) patients. The preclinical data were presented on Dec. 12 at the 2013 Cancer Therapy & Research Center – American Association for Cancer Research (CTRC-AACR) San Antonio Breast Cancer Symposium in San Antonio, Texas.
Help employers find you! Check out all the jobs and post your resume.
